ADMA BIOLOGICS, INC. Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months
ADMA BIOLOGICS, INC. (ADMA) had Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months of $140.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Rolling Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths · last filed 2025-03-18
- 2024-12-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $140.00K.
- 2024-09-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $140.00K.
- 2024-06-30: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $132.00K.
- 2024-03-31: Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months $56.00K.
| Period end | Finite-Lived Intangible Assets, Amortization Expense, Next Rolling Twelve Months |
|---|---|
| 2024-12-31 | $140.00K 10-K · filed 2025-03-18 |
| 2024-09-30 | $140.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $132.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $56.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $351.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | $298.06K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $298.06K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $298.06K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $715.35K 10-K · filed 2023-03-23 |
| 2022-09-30 | $715.35K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $715.35K 10-Q · filed 2022-08-10 |
| 2022-03-31 | $715.35K 10-Q · filed 2022-05-11 |
| 2021-12-31 | $715.35K 10-K · filed 2022-03-24 |
| 2021-09-30 | $715.35K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $715.35K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |